- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Example 1 [US20090137530] | MT-1303 | MT1303
Compound class: Synthetic organic
Comment: Amiselimod (MT-1303) is claimed in patent US20090137530 (Compound 1-3 is the hydrochloride used experimentally) as a potential immunomodulatory agent . It is a sphingosine-1-phosphate (SIP) receptor prodrug agonist, similar in action to the approved MS drug fingolimod, but with improved receptor subtype selectivity .
Selective SIP1 receptor agonists are being investigated for immunomodulatory/immunosuppresant action in MS and other autoimmune conditions .
|No information available.|
|Summary of Clinical Use|
|Amiselimod (MT-1303) has completed Phase 2 dose-finding clinical trials in patients with relapsing-remitting multiple sclerosis (NCT01742052) and moderate to severe chronic plaque psoriasis (NCT01987843). Phase 2 trials in Crohn's disease patients are underway.|
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT01742052||Dose-finding Study of MT-1303||Phase 2 Interventional||Mitsubishi Tanabe Pharma Corporation|
|NCT01987843||Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis||Phase 2 Interventional||Mitsubishi Tanabe Pharma Corporation|